Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) strong earnings report was rewarded with a positive stock price move. Our analysis found some more factors that we think are good for shareholders.
A Closer Look At Ironwood Pharmaceuticals' Earnings
One key financial ratio used to measure how well a company converts its profit to free cash flow (FCF) is the accrual ratio. The accrual ratio subtracts the FCF from the profit for a given period, and divides the result by the average operating assets of the company over that time. You could think of the accrual ratio from cashflow as the 'non-FCF profit ratio'.
Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. That is not intended to imply we should worry about a positive accrual ratio, but it's worth noting where the accrual ratio is rather high. That's because some academic studies have suggested that high accruals ratios tend to lead to lower profit or less profit growth.
Over the twelve months to September 2026, Ironwood Pharmaceuticals recorded an accrual ratio of -0.35. That implies it has very good cash conversion, and that its earnings in the last year actually significantly understate its free cash flow. To wit, it produced free cash flow of US$205m during the period, dwarfing its reported profit of US$149.6m. Ironwood Pharmaceuticals' free cash flow improved over the last year, which is generally good to see.
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
Our Take On Ironwood Pharmaceuticals' Profit Performance
As we discussed above, Ironwood Pharmaceuticals' accrual ratio indicates strong conversion of profit to free cash flow, which is a positive for the company. Because of this, we think Ironwood Pharmaceuticals' underlying earnings potential is as good as, or possibly even better, than the statutory profit makes it seem! Furthermore, it has done a great job growing EPS over the last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. If you'd like to know more about Ironwood Pharmaceuticals as a business, it's important to be aware of any risks it's facing. Be aware that Ironwood Pharmaceuticals is showing 3 warning signs in our investment analysis and 2 of those are significant...
This note has only looked at a single factor that sheds light on the nature of Ironwood Pharmaceuticals' profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.